Table 2 Association between clinicopathological features with B7-H3, B7-H4, and PD-L1 expression in primary tumors.
From: B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma
Characteristics | n (%) | B7-H3 expression | B7-H4 expression | PD-L1 expression | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | P value | Positive | Negative | P value | Positive | Negative | P value | ||
All cases | 805 | 410 | 395 | 234 | 571 | 235 | 570 | |||
Sex | 0.310 | 0.177 | 0.417 | |||||||
Male | 446 (55.4%) | 220 (49.3%) | 226 (50.7%) | 121 (27.1%) | 325 (72.9%) | 125 (28%) | 321 (72%) | |||
Female | 359 (44.6%) | 190 (52.9%) | 169 (47.1%) | 113 (31.5%) | 246 (68.5%) | 110 (30.6%) | 249 (69.4%) | |||
Age (years) | 0.259 | 0.947 | 0.342 | |||||||
<60 | 432 (53.7%) | 228 (52.8%) | 204 (47.2%) | 126 (29.2%) | 306 (70.8%) | 120 (27.8%) | 312 (72.2%) | |||
≥60 | 373 (46.3%) | 182 (48.8%) | 191 (51.2%) | 108 (29%) | 265 (71%) | 115 (30.8%) | 258 (69.2%) | |||
Tumor location | 0.127 | 0.945 | 0.299 | |||||||
Rectum | 417 (51.8%) | 198 (47.5%) | 219 (52.5%) | 120 (28.8%) | 297 (71.2%) | 115 (27.6%) | 302 (72.4%) | |||
Left colon | 217 (27%) | 118 (54.4%) | 99 (45.6%) | 65 (30%) | 152 (70%) | 62 (28.6%) | 155 (71.4%) | |||
Right colon | 171 (21.2%) | 94 (55%) | 77 (45%) | 49 (28.7%) | 122 (71.3%) | 58 (33.9%) | 113 (66.1%) | |||
Tumor differentiation | 0.429 | 0.093 | 0.607 | |||||||
Well-moderate | 736 (91.4%) | 378 (51.4%) | 358 (48.6%) | 220 (29.9%) | 516 (70.1%) | 213 (28.9%) | 523 (71.1%) | |||
Poor | 69 (8.6%) | 32 (46.4%) | 37 (53.6%) | 14 (20.3%) | 55 (79.7%) | 22 (31.9%) | 47 (68.1%) | |||
TNM stage | <0.001 | 0.004 | 0.089 | |||||||
I-II | 342 (42.5%) | 146 (42.7%) | 196 (57.3%) | 81 (23.7%) | 261 (76.3%) | 89 (26%) | 253 (74%) | |||
III-IV | 463 (57.5%) | 264 (57%) | 199 (43%) | 153 (33%) | 310 (67%) | 146 (31.5%) | 317 (68.5%) | |||
MMR status | 0.926 | 0.440 | 0.023 | |||||||
dMMR | 68 (8.4%) | 35 (51.5%) | 33 (48.5%) | 17 (25%) | 51 (75%) | 28 (41.2%) | 40 (58.8%) | |||
pMMR | 737 (91.6%) | 375 (50.9%) | 362 (49.1%) | 217 (29.4%) | 520 (70.6%) | 207 (28.1%) | 530 (71.9%) | |||
Adjuvant treatment | 0.336 | 0.953 | 0.055 | |||||||
No | 242 (30.1%) | 117 (48.3%) | 125 (51.7%) | 70 (28.9%) | 172 (71.1%) | 82 (33.9%) | 160 (66.1%) | |||
Yes | 563 (69.9%) | 293 (52%) | 270 (48%) | 164 (29.1%) | 399 (70.9%) | 153 (27.2%) | 410 (72.8%) | |||
KRAS mutationa | 0.970 | 0.313 | 0.071 | |||||||
Yes | 129 (16%) | 66 (51.2%) | 63 (48.8%) | 41 (31.8%) | 88 (68.2%) | 45 (34.9%) | 84 (65.1%) | |||
No | 181 (22.5%) | 93 (51.4%) | 88 (48.6%) | 48 (26.5%) | 133 (73.5%) | 46 (25.4%) | 135 (74.6%) | |||
